The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men ...

One of the biggest challenges in cancer treatment is chemoresistance: Tumors that initially respond well to chemotherapy ...

This is a preview. Log in through your library . Abstract Homologous recombination is a key process for maintaining genome integrity and diversity. In eukaryotes, the nucleosome structure of chromatin ...

Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance.

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

Identification of variants influences treatment decisions. Inhibitors of the poly-ADP-ribose polymerase (PARP) system, a pathway for repairing single-stranded DNA breaks, are recommended for tumors ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...

A recent study, undertaken by researchers at the Tokyo Metropolitan University and the Tokyo Metropolitan Institute of Medical Science (both Japan), unravels key steps in the process of homologous ...